Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: Placebo|BIOLOGICAL: GLSI-100
Sponsor: Greenwich LifeSciences, Inc.